Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health. The company's lead candidate, CMX001, is being developed as a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA (dsDNA) viral diseases. Over 350 people have received CMX001 to date, with a growing body of evidence supporting the drug's antiviral activity in humans. Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of cytomegalovirus (CMV) in hematopoietic stem cell transplant patients (CMX001-201), a Phase 2 study being initiated for the treatment of adenovirus (AdV) infection in pediatric and adult hematopoietic stem cell transplant patients (CMX001-202), and an Open-Label Study (CMX001-350) for the treatment of any of 12 different dsDNA viral infections, including AdV, herpes viruses such as CMV, herpes simplex virus and Epstein Barr virus, polyoma viruses such as BK virus and JC virus, and pox viruses. The Open-Label Study builds on Chimerix's extensive experience working with clinicians at over 55 leading institutions in the United States, Canada, Europe and Israel who have sought CMX001 for the treatment of more than 150 immunocompromised patients under Emergency INDs. CMX001 has been well tolerated in all studies. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release. Chimerix has received significant federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases. Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing. Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.Founded in 2000, Chimerix is an established company that loves to hire graduates from University of St. Francis, with 11.1% of its employees having attended University of St. Francis. Want to compare Chimerix to some other great places to work in Durham, NC? We suggest taking a look at Zippia's list of Best Companies to Work For in Durham, NC.Chimerix is a small health care company based in Durham, NC with only 82 employees and an annual revenue of $212,000.
Chimerix's mission statement
To develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.
In demand companies are hiring! Let Zippia apply for you!
The founders of Chimerix are George Painter and Timothy Wollaeger.
The key people at Chimerix are Michael Sherman, George Painter and Timothy Wollaeger.
Key people
Michael Sherman
George Painter
Timothy Wollaeger
Chimerix rankings
Chimerix is ranked #90 on the Best Health Care companies to work for in North Carolina list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of companies. Rankings are based on government and proprietary data on salaries, company financial health, and employee diversity.
Rate Chimerix's commitment to diversity and inclusion.
Do you work at Chimerix?
Did Chimerix's compensation package meet your expectations?
Videos about working at Chimerix
Chimerix Refuses to Save the Life of Josh Hardy
Chimerix financial performance
9.3
Performance score
We calculated the performance score of companies by measuring multiple factors, including revenue, longevity, and stock market performance.
Chimerix currently has 33.8M in revenue. Chimerix's most recent quarter produced 11.0k (q3'2023).
Chimerix annual revenue
$34M
$27M
$20M
$14M
$7M
$0
2019
2020
2021
2022
2023
2024
Highest paying Chimerix competitors
Compare Chimerix salaries to competitors, including BioMarin, BioCryst Pharmaceuticals, and Insmed. Employees at BioMarin earn the highest average yearly salary of $87,259. The salaries at BioCryst Pharmaceuticals average $85,535 per year, and the salaries at Insmed come in at $81,784 per year.
Rank
Company
Average salary
Jobs
1
$87,259
0
2
$85,535
0
3
$81,784
0
4
$75,394
0
5
$48,962
0
Are you an executive, HR leader, or brand manager at Chimerix?
Claiming and updating your company profile on Zippia is free and easy.
Zippia gives an in-depth look into the details of Chimerix, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Chimerix. The employee data is based on information from people who have self-reported their past or current employments at Chimerix. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Chimerix. The data presented on this page does not represent the view of Chimerix and its employees or that of Zippia.
Chimerix may also be known as or be related to CHIMERIX INC, Chimerix, Chimerix Inc and Chimerix, Inc.
